Evidence map›Paper›PMID 33992534›Full record

ArticleTrends in cancer2021

Retrotransposons: Jump to Cancer?

Yangjun Wu, Xiaohua Wu, Shengli Li

Abstract readComment
PubMed Publisher
In one paragraph

Article in Trends in cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Yangjun WuDepartment of Gynecological Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Xiaohua WuDepartment of Gynecological Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Shengli LiInstitute of Translational Medicine, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 201620, China. Electronic address: shengli.li@shsmu.edu.cn.
Fudan University Shanghai Cancer Center · CNShanghai Jiao Tong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Retrotransposons have been known as major sources of genomic instability that trigger and promote cancer development. In a recent study, Gu et al. revealed that MPP8 deficiency impeded tumor development through reactivation long interspersed element-1 (LINE-1 or L1) retrotransposons in acute myeloid leukemia (AML), suggesting a tumor-suppressive role for retrotransposons.

Indexed as

NeoplasmsRetroelementsGenomic InstabilityHumansLong Interspersed Nucleotide ElementsRetroelementsleukemiaLINE-1retrotransposontumor-suppressor

Identifiers

PMID33992534
OpenAlexW3160533098

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.